RNA, U7 small nuclear 110 pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU7-110P profile across patient tissues and cancer cell-line models. RNU7-110P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNU7-110P is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, RNU7-110P RNA expression shows 6,488 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, HNSC, and STAD as cancer lineages where RNU7-110P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU7-110P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU7-110P survival associations across molecular data types. RNU7-110P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU7-110P RNA expression–survival associations across cancer types. High RNU7-110P expression shows unfavorable associations in MESO, ACC, LIHC, LUSC, PAAD and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RNU7-110P RNA expression.
This table summarizes RNU7-110P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU7-110P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU7-110P shows lower tumor expression in LUAD and BRCA and higher tumor expression in HNSC. The HNSC box plot shows higher RNU7-110P RNA expression in tumor versus normal tissue (log2 FC = +0.341, t-test p = .006).
This table shows molecular features associated with RNU7-110P in patient tissues and cancer cell lines. In patient samples, RNU7-110P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
